J. Scott Garland - 01 Oct 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: Director
Issuer ticker: ELVN
Reported as of: 01 Oct 2026
Net transaction value: -$606,719
SEC form: 4
Accepted by SEC: 05 Oct 2026, 16:57:04 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

J. Scott Garland filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 05 Oct 2026.

Key facts

This page summarizes J. Scott Garland's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Oct 2026, 16:57.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$606,719.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001533228 Primary reporting owner

Garland J. Scott

Relationship: Director
Address: C/O ENLIVEN THERAPEUTICS, INC., 205 PARK ROAD, BURLINGAME
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 05 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Options Exercise

Transaction value
Shares: +13,000
Change %
Price: $15.47^*
Shares after: 13,000
Date: 01 Oct 2026
Ownership: Direct

ELVN transaction

Common Stock

Sale

Transaction value: $606,719
Shares: -13,000
Change %: -100%
Price: $46.67
Shares after: 0
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -13,000
Change %: -22%
Price: $0.000000^*
Shares after: 46,372
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $15.47
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed in multiple trades at prices ranging from $46.62 to $46.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F2

The option, originally for 59,372 shares, vests as to 1/36th of the shares on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.